Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
14 August 2020 | Story Andre Damons | Photo Supplied
Max du Preez, Editor: Vrye Weekblad (top left), was the facilitator was the facilitator for Thursday’s UFS Though-Leader webinar that included Prof Salim Abdool Karim, Director: Centre for the AIDS Programme of Research in South Africa (CAPRISA) and Chair: South African Ministerial Advisory Committee on COVID-19 (top right); Prof Glenda Gray, President and CEO: South African Medical Research Council (SAMRC) (bottom left); and Prof Felicity Burt from the UFS and NRF-DST South African Research Chair in Vector-borne and Zoonotic Pathogens Research (bottom right), participated in Thursday’s Though-Leader webinar.

Although the decline in COVID-19 cases is a promising sign for South Africa, there are concerns about a second surge, and the country should not become complacent.

This was the opinion of the three experts who took part in the first Thought-Leader webinar presented by the University of the Free State (UFS) on Thursday, 13 August. The 2020 UFS Thought-Leader Webinar Series, themed 'Post-COVID-19, Post-Crisis', is taking place in collaboration with Vrye Weekblad as part of the Vrystaat Literature Festival’s online initiative, VrySpraak-digitaal.

The panellists included top experts such as Prof Salim Abdool Karim, Director: Centre for the AIDS Programme of Research in South Africa (CAPRISA) and Chair: South African Ministerial Advisory Committee on COVID-19; Prof Glenda Gray, President and CEO: South African Medical Research Council (SAMRC); and the UFS’ Prof Felicity Burt, NRF-DST South African Research Chair in Vector-borne and Zoonotic Pathogens Research.
Prof Karim said the downward decline is consistent and the number of patients presenting at hospitals is also declining.
 
Promising trend of decline
“What we are seeing is a promising trend, and it looks like we are on the decline. A question that I am often asked is: Is the worst over? The answer is not clear-cut. We are concerned about the risk of a second surge. If anything – what really concerns me at this stage is a second surge, as I think about how the pandemic may play out over the next few weeks,” said Prof Karim. 

He also referred to countries such as the US, Spain, New Zealand, Vietnam, and South Korea, which are now facing a second surge. 

“We need to be very careful; this is not the time for complacency. We need to maintain all our efforts. If we look at one of the key drivers, it is the need for our economy to restart. We need to get people back to work,” said Prof Karim. 
According to him, we have to look at COVID-19 not as a sprint, but as a marathon. “As we learn to co-exist with this virus, aim for containment; we need to plan for the long term. Even if we get a vaccine, it is unlikely that we will be able to vaccinate a substantial part of our population before the end of next year.” 

“We need to transition from being scared to a situation where we can control our risk. When we know that we can control the risk and then influence the risk, we influence the risk of everyone around us. Part of the new normal is the strategy of mitigation with prevention, plus preventing outbreaks.”

Schools and vaccine development
Prof Gray spoke about whether schools should be open and the role that children play in transmission, how to avoid the second wave, how to adjust our testing, and the exciting news around vaccine development. 

As a paediatrician and a parent, Prof Gray said she believes schools should open. “Children have a different immune response to COVID-19. They have different immune responses to Coronavirus and they probably have less viral-load copies which makes them have milder diseases. They are lucky to have been spared from symptomatic or severe disease,” said Prof Gray. 

According to her, schools need to be de-risked as much as possible, with children and teachers wearing masks, washing hands, making sure that there is good ventilation in the school and that windows are wide open. 

“We also need to know about the comorbidity and ages of teachers, so that we can keep the sick and older teachers out of direct contact. The younger teachers with no comorbidities should be teaching. 

“We also know from our experiences with health workers that transmissions happen in the tearoom where teachers take off their masks and talk. We need to minimise the transmissions in tearooms and protect teachers and parents who are older and have comorbidities.”  

Prof Gray said from data she has seen, schools play a very small role in the transmission of COVID-19; a lot more (transmissions) happen in the community, by commuting, and overcrowded taxis.

Prof Gray agreed with Prof Karim that we should be concerned about a second wave, and that we need to make sure community transmissions are minimised. 

Regarding a vaccine, Prof Gray said a global race is on to find a vaccine. “The more vaccines the better, we want more vaccines to work. The more vaccines, the more affordable they are, and the more doses are available.”

One health approach

During her presentation, Prof Burt said the current response to outbreaks is largely reactive rather than proactive, and “if we have more of a one-health approach, with forecasting, early detection, and a more rapid response, we could have an impact on public health in the future”. 


News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept